CN102526147A - 一种三七总皂苷的纯化方法及其制剂 - Google Patents
一种三七总皂苷的纯化方法及其制剂 Download PDFInfo
- Publication number
- CN102526147A CN102526147A CN2012100753736A CN201210075373A CN102526147A CN 102526147 A CN102526147 A CN 102526147A CN 2012100753736 A CN2012100753736 A CN 2012100753736A CN 201210075373 A CN201210075373 A CN 201210075373A CN 102526147 A CN102526147 A CN 102526147A
- Authority
- CN
- China
- Prior art keywords
- radix notoginseng
- notoginseng total
- total arasaponins
- total saponins
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 122
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 122
- 229930182490 saponin Natural products 0.000 title claims abstract description 41
- 150000007949 saponins Chemical class 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 41
- 235000017709 saponins Nutrition 0.000 title abstract description 40
- 238000002347 injection Methods 0.000 claims abstract description 34
- 239000007924 injection Substances 0.000 claims abstract description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000011347 resin Substances 0.000 claims abstract description 18
- 229920005989 resin Polymers 0.000 claims abstract description 18
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 16
- 239000004952 Polyamide Substances 0.000 claims abstract description 15
- 229920002647 polyamide Polymers 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 30
- 239000012141 concentrate Substances 0.000 claims description 28
- 239000003480 eluent Substances 0.000 claims description 24
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 15
- 238000009413 insulation Methods 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 229930182494 ginsenoside Natural products 0.000 claims description 12
- 229940089161 ginsenoside Drugs 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims description 9
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000005374 membrane filtration Methods 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 229920006122 polyamide resin Polymers 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000012535 impurity Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 238000005406 washing Methods 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract 1
- 238000004042 decolorization Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 31
- 238000012360 testing method Methods 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000001476 alcoholic effect Effects 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000003727 cerebral blood flow Effects 0.000 description 11
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000009277 Panax notoginseng extract Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- -1 triol saponins Chemical class 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000037906 ischaemic injury Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210075373.6A CN102526147B (zh) | 2012-03-21 | 2012-03-21 | 一种三七总皂苷的纯化方法及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210075373.6A CN102526147B (zh) | 2012-03-21 | 2012-03-21 | 一种三七总皂苷的纯化方法及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102526147A true CN102526147A (zh) | 2012-07-04 |
CN102526147B CN102526147B (zh) | 2014-04-23 |
Family
ID=46334968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210075373.6A Active CN102526147B (zh) | 2012-03-21 | 2012-03-21 | 一种三七总皂苷的纯化方法及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102526147B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536968A (zh) * | 2013-10-21 | 2014-01-29 | 浙江中医药大学 | 三七总皂苷羟基磷灰石仿生复合物的制备方法 |
CN103550102A (zh) * | 2013-11-07 | 2014-02-05 | 广西奥奇丽股份有限公司 | 含田七总皂苷和愈创木薁磺酸钠的中草药牙膏 |
CN104892715A (zh) * | 2015-05-06 | 2015-09-09 | 许庆彤 | 人参二醇皂苷元的制备方法 |
CN111035719A (zh) * | 2020-01-17 | 2020-04-21 | 金陵药业股份有限公司 | 一种从脉络宁注射液生产废液中提取总皂苷的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1609114A (zh) * | 2004-06-18 | 2005-04-27 | 海南亚洲制药有限公司 | 三七叶总黄酮其制备方法及应用 |
CN101244105A (zh) * | 2008-03-04 | 2008-08-20 | 文山壮族苗族自治州三七科学技术研究所 | 三七标准提取物p1237,其药物组合物,其制备方法和其用途 |
CN101463061A (zh) * | 2007-12-21 | 2009-06-24 | 中国医学科学院药物研究所 | 三七中人参皂苷Rg1、Rb1及其总皂苷的制备方法 |
-
2012
- 2012-03-21 CN CN201210075373.6A patent/CN102526147B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1609114A (zh) * | 2004-06-18 | 2005-04-27 | 海南亚洲制药有限公司 | 三七叶总黄酮其制备方法及应用 |
CN101463061A (zh) * | 2007-12-21 | 2009-06-24 | 中国医学科学院药物研究所 | 三七中人参皂苷Rg1、Rb1及其总皂苷的制备方法 |
CN101244105A (zh) * | 2008-03-04 | 2008-08-20 | 文山壮族苗族自治州三七科学技术研究所 | 三七标准提取物p1237,其药物组合物,其制备方法和其用途 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536968A (zh) * | 2013-10-21 | 2014-01-29 | 浙江中医药大学 | 三七总皂苷羟基磷灰石仿生复合物的制备方法 |
CN103550102A (zh) * | 2013-11-07 | 2014-02-05 | 广西奥奇丽股份有限公司 | 含田七总皂苷和愈创木薁磺酸钠的中草药牙膏 |
CN104892715A (zh) * | 2015-05-06 | 2015-09-09 | 许庆彤 | 人参二醇皂苷元的制备方法 |
CN111035719A (zh) * | 2020-01-17 | 2020-04-21 | 金陵药业股份有限公司 | 一种从脉络宁注射液生产废液中提取总皂苷的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102526147B (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100455291C (zh) | 一种治疗心脑血管疾病的三七药物组合物 | |
CN101829170A (zh) | 一种三七总皂苷提取物及其制备方法 | |
CN102600219A (zh) | 黄蜀葵花总黄酮提取物及其制备方法 | |
CN1833692B (zh) | 一种假马齿苋提取物及其制备方法和用途 | |
CN102526147B (zh) | 一种三七总皂苷的纯化方法及其制剂 | |
CN102274260B (zh) | 一种三七提取物的药物组合物及其制备方法 | |
CN102134268B (zh) | 竹节参皂苷Ⅳa制备方法以及在制备保肝降酶药物中的应用 | |
CN103565866A (zh) | 一种三七总皂苷的制备方法 | |
CN107412430A (zh) | 一种玄参水提物及其应用 | |
CN110680802B (zh) | 汉防己甲素注射液及其制备方法 | |
CN107722080A (zh) | 一种从岩白菜叶中提取熊果苷的方法 | |
CN100484557C (zh) | 一种治疗心肌缺血、改善微循环的中药复方制剂及其制备方法 | |
CN103381200A (zh) | 一种桑白皮总生物碱提取物及其制备应用 | |
CN103800418B (zh) | 一种活血止痛组合物及胶囊制备工艺和应用 | |
CN102335213A (zh) | 一种低毒的三七总皂苷注射剂及其制备方法 | |
CN103655653A (zh) | 大孔弱酸性松香基阳离子交换树脂吸附三七总皂苷毒性成分的用途 | |
CN1698717B (zh) | 一种中药复方脂肪乳注射液及其制备方法 | |
CN107095893B (zh) | 一种太白三七活性物质的提取方法及其应用 | |
CN102145043A (zh) | 一种治疗心血管疾病的药物组合物及其制剂,以及制剂的制备方法 | |
CN101974011B (zh) | 一种具有药用活性的新化合物灯盏细辛酸甲酯 | |
CN101322734B (zh) | 具有抗炎免疫作用的轮叶党参总皂苷及其制备方法 | |
CN100534461C (zh) | 一种治疗糖尿病及糖耐量低减的药物组合物及制备方法 | |
CN109223739B (zh) | 一种组合物及其制备方法和应用 | |
CN1951432A (zh) | 参附组合物、制剂及其制备方法和用途 | |
CN102716231B (zh) | 一种治疗脑损伤和脑水肿的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for purifying panax notoginseng total saponins and preparation of panax notoginseng total saponins Effective date of registration: 20191125 Granted publication date: 20140423 Pledgee: Shenyang Shengjing Financing Guarantee Co., Ltd Pledgor: Beijing Zhonghaikang Medical Technology Development Co., Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201201 Granted publication date: 20140423 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A purification method and preparation of Panax notoginseng saponins Effective date of registration: 20201202 Granted publication date: 20140423 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211011 Granted publication date: 20140423 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |